Mode
Text Size
Log in / Sign up

Adult T-cell leukemia/lymphoma

Part of Cancer

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for Adult T-cell leukemia/lymphoma

10 trials tracked for Adult T-cell leukemia/lymphoma.

10Trials tracked
0Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 2 8 Phase 1 2
  1. Phase 2 KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL) Completed
  2. Phase 2 EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia Lymphoma Completed
  3. Phase 2 Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma Completed
  4. Phase 2 Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma Completed
  5. Phase 2 Lenalidomide in HTLV-1 Adult T-Cell Leukemia Completed
  6. Phase 2 Phase II Study of KW-0761 in Subjects With CCR4-positive Adult T-cell Leukemia-lymphoma Completed
Show 4 more trials
  1. Phase 2 A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL) Completed
  2. Phase 2 A Phase 2 Study of Lenalidomide in Patients With Relapsed or Recurrent Adult T-cell Leukemia-lymphoma Completed
  3. Phase 1 A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy Completed
  4. Phase 1 Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome Completed

Showing the 10 most-cited and recently-updated of 10 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

Research across Cancer

Related studies from across the Cancer family.

VRE Prevalence 18.4% in Hematologic Malignancy Patients, Pooled Meta-Analysis Finds
Primary Care & Family Medicine Meta-analysis
VRE Prevalence 18.4% in Hematologic Malignancy Patients, Pooled Meta-Analysis Finds Vancomycin-resistant Enterococcus is common in patients with certain blood cancers
This meta-analysis of 120 studies estimates the pooled prevalence of vancomycin-resistant Enterococcus (VRE) in patients with hematological …
A large review of 120 studies shows that nearly 1 in 5 patients with leukemia or lymphoma carry a resistant strain of bacteria.
Evaluating Cytokine and Molecular Biomarkers for Diagnosing Primary Vitreoretinal Lymphoma
Hematology Meta-analysis
Evaluating Cytokine and Molecular Biomarkers for Diagnosing Primary Vitreoretinal Lymphoma Biomarkers Show Promise in Detecting Vitreoretinal Lymphoma
A meta-analysis identifies the IL-10 to IL-6 ratio and MYD88 as high-performing biomarkers for distinguishing vitreoretinal lymphoma from in…
New research identifies specific biomarkers that may help doctors more accurately detect and diagnose a rare type of eye cancer.
Blinatumomab plus chemotherapy improves disease-free and overall survival in pediatric B-ALL
Hematology Meta-analysis
Blinatumomab plus chemotherapy improves disease-free and overall survival in pediatric B-ALL Trial shows blinatumomab improves survival for pediatric B-cell leukemia
This meta-analysis of randomized trials found that adding blinatumomab to chemotherapy improved disease-free survival (RR 0.63) and overall …
Adding blinatumomab to chemotherapy may improve survival rates for children with specific types of high-risk or relapsed B-cell leukemia.
Brexucabtagene autoleucel achieves 88% overall response rate in relapsed or refractory mantle cell lymphoma
Oncology Meta-analysis
Brexucabtagene autoleucel achieves 88% overall response rate in relapsed or refractory mantle cell lymphoma Trial Shows Brexucabtagene Autoleucel Provides Durable Benefit for Blood Cancers
This meta-analysis of 31 cohorts evaluates brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma and B-cell acute lympho…
Brexucabtagene autoleucel shows high response rates and durable benefits for adults with specific types of relapsed or refractory blood canc…
Exercise interventions improve bone mineral density, cardiorespiratory endurance, and quality of life in children with acute leukemia
Pediatrics Meta-analysis
Exercise interventions improve bone mineral density, cardiorespiratory endurance, and quality of life in children with acute leukemia Exercise May Help Kids With Leukemia Feel and Move Better
This best evidence summary synthesizes 16 systematic reviews and 2 clinical practice guidelines regarding exercise interventions for childre…
Exercise may improve bone strength, fitness, and quality of life in children with acute leukemia, a new evidence summary suggests.
Multiparametric MRI and image-guided neurointerventions provide critical roles in brain tumor management and surveillance
Radiology & Imaging Sys. Review
Multiparametric MRI and image-guided neurointerventions provide critical roles in brain tumor management and surveillance Advanced Imaging and Interventions Improve Brain Tumor Management
This narrative review examines the roles of advanced diagnostic imaging and image-generated neurointerventions in managing brain tumors, inc…
Newer imaging techniques and minimally invasive procedures are expanding how doctors detect, plan, and treat various types of brain tumors.
EBV prevalence varies widely across lymphoma subtypes, highest in ENKTL at 92.4%
Hematology Meta-analysis
EBV prevalence varies widely across lymphoma subtypes, highest in ENKTL at 92.4% EBV Presence Linked to Lymphoma Cases in People with HIV
This meta-analysis of 307 studies and over 21,140 lymphoma cases quantifies Epstein-Barr virus (EBV) prevalence across lymphoma subtypes, st…
A large review of over 21,000 cases shows that the Epstein-Barr virus is more common in certain lymphoma types among people living with HIV.
Deep learning for leukemia diagnosis faces fragmented research and limited multimodal integration in current literature
Hematology Sys. Review
Deep learning for leukemia diagnosis faces fragmented research and limited multimodal integration in current literature AI for leukemia diagnosis still fragmented, review finds
This scoping review evaluates deep learning techniques for leukemia detection across morphological, immunophenotyping, and molecular modalit…
A new review shows AI tools for leukemia diagnosis are promising but fragmented, with few using multiple data types.
CircRNAs act as signaling hubs for immune checkpoints and indicators of ICI response in lymphoma
Genetics & Precision Medicine Sys. Review
CircRNAs act as signaling hubs for immune checkpoints and indicators of ICI response in lymphoma CircRNAs May Help Predict Response to Lymphoma Immunotherapy
This systematic review examines the role of circRNAs, including EBV-encoded types, in immune evasion within lymphomas. The authors conclude …
New research suggests that specific molecules called circRNAs could help doctors predict how patients with lymphoma will respond to immune c…
Mosunetuzumab plus polatuzumab vedotin achieved a 100% overall response rate in Japanese patients with LBCL
Hematology RCT
Mosunetuzumab plus polatuzumab vedotin achieved a 100% overall response rate in Japanese patients with LBCL Trial shows promising results for relapsed large B-cell lymphoma
This Phase III randomized controlled trial analyzed a subgroup of 16 Japanese patients with relapsed or refractory large B-cell lymphoma. Th…
A new treatment combination showed a high response rate and longer progression-free survival for patients with a specific type of lymphoma.
Axicabtagene ciloleucel shows higher early response but greater toxicity than tisagenlecleucel in large B-cell lymphoma
Oncology Meta-analysis
Axicabtagene ciloleucel shows higher early response but greater toxicity than tisagenlecleucel in large B-cell lymphoma Comparison of two CAR-T cell therapies for lymphoma
This meta-analysis compared axicabtagene ciloleucel and tisagenlecleucel for the treatment of large B-cell lymphoma. While axicabtagene cilo…
New data comparing axicabtagene ciloleucel and tisagenlecleucel shows different levels of early response and safety risks for lymphoma patie…
Anti-CD19 shRNA-engineered CAR-T cells achieve an 88% overall response rate in B-cell acute lymphoblastic leukemia
Oncology Meta-analysis
Anti-CD19 shRNA-engineered CAR-T cells achieve an 88% overall response rate in B-cell acute lymphoblastic leukemia CAR-T Cells Show Promise for B-cell Acute Lymphoblastic Leukemia
This meta-analysis evaluates anti-CD19 shRNA-engineered CAR-T cells (interleukin-6 knockdown) for patients with B-cell acute lymphoblastic l…
New research into modified CAR-T cells shows high response rates in patients with a specific type of leukemia while managing serious side ef…